• Eden Empire Inc. (EDEN) announces a non-brokered private placement of units at a price of C$0.12 per unit for gross proceeds of up to C$1,000,000
  • A unit is comprised of one common share and one common share purchase warrant
  • Proceeds will be used to fund the operation of retail cannabis stores and for general and working capital purposes
  • Eden Empire is in the business of investments and operations in the cannabis sector and engaging in retail cannabis sales.
  • Eden Empire Inc. (EDEN) opened trading at C$0.13 per share.

Eden Empire Inc. (EDEN) announces a non-brokered private placement of units for gross proceeds of up to C$1,000,000. 

A unit is comprised of one common share and one common share purchase warrant. ‎Each warrant entitles the holder to acquire one common share of the company at a price of ‎C$0.20 for a period of 24 months from the date of issuance.

If the daily volume-weighted average price of the company’s common shares on the Canadian Securities Exchange is $0.40 per share or greater for any ten consecutive trading days while the warrants are outstanding, Eden may choose to accelerate the expiry date of the warrants to be 30 days following the date of a notice or news release.

Proceeds will be used to fund the operation of retail cannabis stores in the United States and Canada and for general and working capital purposes.

The closing of the Private Placement is subject to the approval of the CSE.

Eden Empire is in the business of investments and operations in the cannabis sector and engaging in retail cannabis sales.

Eden Empire Inc. (EDEN) opened trading at C$0.13 per share.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.